4th Annual Antibody Therapeutics - December 12-14, 2006

Antibody Therapeutics
Advancing Clinical Development of Therapeutic Antibodies
December 12-14, 2006 - San Diego Convention Center - San Diego, CA
IBC's 4th Annual Antibody Therapeutics provides a focused look at the clinical development of antibody drug products, and offers perspectives on the business, legal, regulatory and technical issues surrounding this important class of biopharmaceuticals. By attending, you will gain valuable perspectives on the progress of antibody therapeutics in trials and learn strategies you can employ to improve the safety and functional performance of your antibody products.
Program Highlights Include...
Amgen, Genmab, M.D. Anderson Cancer Center and the University of Utah report on the clinical progress of antibody therapeutics now in trials
Genentech and Amgen present lessons learned in preclinical toxicology studies - and how these can be applied to the development of next-generation molecules
Biotec Pharmacon describes the outcome of clinical studies testing the concept of using oral SBG to enhance the anti-cancer efficacy of injected mAbs
Medarex outlines an integrated approach to the development of antibody conjugates - separately selecting the antibody, linker and cytotoxic agent
Algonomics assesses the primary causes of immunogenicity of antibody therapeutics in various diseases areas
Rice University shares its work in conjugating nanoparticles to antibodies to improve the targeting of tumor cells or tumor vasculature
Track Clinical Progress and Business Trends in an Antibody Therapeutics Market Growing at More Than 40% Annually!
New updates on the clinical development of antibody therapeutics
Large and small company perspectives on antibody deal making
In-depth analysis of the primary immunogenicity drivers for antibody therapeutics
Progress in developing second generation antibody therapeutics
Strategies for generating new sources of revenue with antibody patents
--------------------------------------------------------------------------------
Scientific Advisory Board
Mark R. Alfenito, Ph.D., President, KaloBios Pharmaceuticals Inc.
Benjamin P. Chen, Ph.D., Managing Director, Burrill & Company
Rathin C. Das, Ph.D., Chief Business Officer, President, Affitech AS/ Affitech USA, Inc. (Chairman)
Nils Lonberg, Ph.D., Senior Vice President and Scientific Director, Medarex Inc.
Keynote Presentations
The Influence of Isotype, Glycoform and Epitope Specificity on the Functional Profile of Antibody Therapeutics
Roy Jefferis, Ph.D., Professor of Molecular Immunology, Division of Immunity & Infection, University of Birmingham, United Kingdom
Antibodies to Phosphatidylserine for Targeting Tumor Blood Vessels And Viruses
Philip E. Thorpe, Ph.D., Serena S. Simmons Distinguished Chair in Cancer Immunopharmacology, University of Texas Southwestern Medical Center
Your Registration Includes Access to THREE Events in One Location with One Exhibit Hall!
As a registered delegate for the Antibody Engineering conference, you will have access to the sessions and materials of two concurrent meetings. You may move freely among the sessions of all three events and customize your conference experience to meet the needs of you and your organization.
IBC's 17th Annual International Conference
Antibody Engineering
Antibody Engineering and Immunotherapeutics for the 21st Century
December 10-14, 2006
Now entering its 17th year, IBC's Antibody Engineering has attained a well-deserved reputation as the pre-eminent meeting of its type anywhere in the world. This five-day meeting presents an international speaker faculty of more than 50 leading scientists discussing advances in basic science, therapeutic development (in adapative/innate immunity, HIV, pathogenic disease and cancer) and biodefense. The meeting also features an important new session and panel discussion on the application of systems biology in setting antibody standards.
? Review the complete program
IBC's 2nd Annual International Conference
Protein Engineering for Biotherapeutics
Developing and Improving Next-Generation Biotherapeutics
December 12-14, 2006
The 2nd Annual Protein Engineering for Biotherapeutics offers a look into the future of protein engineering as applied to the development of biologic drugs. A full day is dedicated to the leading examples of a new class of biotherapeutics based on non-antibody scaffolds. And, you'll see how protein engineering can affect the functional qualities of biotherapeutics ? stability, improved pharmacodynamic properties, reduced immunogenicity and novel routes of administration.
? Review the complete program

Team Discount: Register 3, the 4th goes FREE!
When three members of the same company register for the conference at the same time, the fourth attends for FREE! Complete registration forms for all parties must be sent together with complete payments for the entire group to qualify for team discounts. No partial payments or registrations sent without payment are eligible for this discount. Note: The free registration will be applied to the lowest conference fee option.